Letrozole Accord Healthcare Ireland

Letrozole, the active ingredient in Letrozole Accord Healthcare Ireland, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways, reducing estrogen levels to inhibit tumor growth.

- Hormone receptor‑positive breast cancer in postmenopausal women: decreases estrogen production to slow tumor progression. - Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: helps prevent disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: reduces disease progression and improves survival outcomes.

Letrozole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness. - Headache: mild to moderate pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fractures: increased risk due to lowered estrogen. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Severe allergic reactions: rash, swelling, difficulty breathing. - QT interval prolongation: potential heart rhythm disturbances. - Hypercholesterolemia: significant rise in cholesterol levels.

When prescribing Letrozole, clinicians should consider several safety measures.

- Bone health monitoring: assess bone mineral density regularly. - Liver function testing: evaluate hepatic enzymes before and during therapy. - Cardiovascular risk assessment: monitor for signs of thrombosis. - Drug interaction review: check concomitant medications for potential interactions. - Patient counseling: inform about hot flashes and fatigue. - Store at ambient temperature: keep in original packaging, protect from moisture.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce Letrozole effectiveness. - Estrogen‑containing hormonal therapies: can counteract aromatase inhibition. - Tamoxifen: antagonistic action may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: Letrozole may increase INR and bleeding risk. - Statins: possible heightened risk of myopathy. - SSRIs (e.g., fluoxetine): may alter Letrozole metabolism. - Anticonvulsants (e.g., carbamazepine): may affect plasma levels. - Antifungal agents (e.g., ketoconazole): could increase Letrozole exposure.